Sponsor or institution

Clinical trials and research at Shanghai Juncell Therapeutics

• 15Clinical trials
• 1Country

Newest trials

All recruiting trials (15)

• GC101-NSCLC: A Phase 2 test using a patient’s own tumor-infiltrating lymph cells

  This phase II trial tests autologous tumor-infiltrating lymphocytes (TILs) in adults up to age 70 with non-small cell lung cancer to see if the treatment helps control the disease after standard therapy.

  Recruiting Phase 2 Shanghai Juncell Therapeutics · Shanghai · NCT07560111

• GC203 TIL therapy for advanced solid tumors in adults

  This trial tests GC203 tumor-infiltrating lymphocyte therapy in adults with solid tumors that have not responded to standard treatments.

  Recruiting Phase 1 Shanghai Juncell Therapeutics · Shenzhen · NCT07256756

• GC203 tumor-infiltrating lymphocyte therapy for pancreatic ductal adenocarcinoma

  This trial will test whether gene-edited tumor-infiltrating lymphocytes (GC203 TIL), given after mild lymphodepletion, are safe and can help people with pancreatic ductal adenocarcinoma who have not responded to standard treatments.

  Recruiting Early Phase 1 Shanghai Juncell Therapeutics · Shanghai, Shanghai Municipality · NCT06828328

• Using tumor-infiltrating lymphocytes to treat advanced melanoma

  This study is testing a new treatment using patients' own immune cells to see if it works better than standard chemotherapy for people with advanced melanoma.

  Recruiting Phase 2 Shanghai Juncell Therapeutics · Beijing · NCT06703398

• Using tumor infiltrating lymphocytes to treat advanced solid tumors

  This study is testing a new treatment using specially modified immune cells from tumors to see if it can help people with advanced solid tumors feel better.

  Recruiting Early Phase 1 Shanghai Juncell Therapeutics · Shanghai · NCT06488950

• Using patients' own immune cells to treat advanced lung cancer

  This study is testing if using patients' own immune cells can help people with advanced lung cancer that hasn't responded to other treatments.

  Recruiting Phase 1 Shanghai Juncell Therapeutics · Shanghai · NCT06473961

• Injecting engineered immune cells to treat advanced solid tumors

  This study is testing a new treatment that uses specially modified immune cells taken from patients' tumors to see if it can help people with advanced cancers that haven't responded to other treatments.

  Recruiting Phase 1 Shanghai Juncell Therapeutics · Shanghai · NCT06375187

• Using tumor infiltrating lymphocytes to treat advanced breast cancer

  This study is testing a new treatment using immune cells from tumors to see if it can help people with advanced breast cancer who haven't had success with other therapies.

  Recruiting Early Phase 1 Shanghai Juncell Therapeutics · Shanghai · NCT05142475

• Using tumor infiltrating lymphocytes to treat advanced liver and pancreatic cancers

  This study is testing a new treatment using immune cells from tumors to see if it can help people with advanced liver and pancreatic cancers who haven't responded to regular therapies.

  Recruiting Early Phase 1 Shanghai Juncell Therapeutics · Shanghai, Shanghai Municipality · NCT05098197

• Using tumor infiltrating lymphocytes to treat advanced melanoma

  This study is testing if a new treatment using immune cells from patients' own tumors can help people with advanced melanoma who haven't had success with other therapies.

  Recruiting Early Phase 1 Shanghai Juncell Therapeutics · Shanghai · NCT05098184

• Treatment of advanced gynecologic tumors using modified TIL therapy

  This study is testing a new treatment using modified immune cells to see if it can help people with advanced gynecologic tumors fight their cancer more effectively.

  Recruiting Early Phase 1 Shanghai Juncell Therapeutics · Shanghai, Shanghai Municipality · NCT05098171

• Using tumor infiltrating lymphocytes to treat advanced solid tumors

  This study is testing a new treatment using immune cells from patients' own tumors to see if it can help people with advanced solid tumors who haven't responded to other therapies.

  Recruiting Early Phase 1 Shanghai Juncell Therapeutics · Hangzhou, Zhejiang · NCT05087745

• Using tumor infiltrating lymphocytes to treat advanced solid tumors

  This study is testing a new treatment using immune cells from tumors to see if it can help people with advanced solid tumors that haven’t responded to regular therapies.

  Recruiting Early Phase 1 Shanghai Juncell Therapeutics · Shanghai · NCT04967833

• Using tumor infiltrating lymphocytes to treat advanced gastrointestinal tumors

  This study is testing a new treatment using immune cells from patients' own tumors to see if it can help people with advanced gastrointestinal cancers that haven't responded to other therapies.

  Recruiting Early Phase 1 Shanghai Juncell Therapeutics · Shanghai · NCT04960072

• Using tumor infiltrating lymphocytes to treat brain glioma

  This study is testing a new treatment using patients' own immune cells to see if it can help people with aggressive brain tumors that haven't improved with other therapies.

  Recruiting Early Phase 1 Shanghai Juncell Therapeutics · Suzhou, Jiangsu · NCT04943913

Quick answers

How many clinical trials run by Shanghai Juncell Therapeutics are recruiting right now?

15, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Early Phase 1: 10, Phase 1: 3, Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →